Iovance Biotherapeutics (IOVA) Accumulated Expenses (2011 - 2026)

Iovance Biotherapeutics (IOVA) has reported Accumulated Expenses for 16 consecutive years, with $88.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 3.97% year-over-year to $88.1 million; the TTM figure through Mar 2026 stood at $88.1 million (up 3.97% YoY), while the FY2025 annual figure was $111.2 million, up 35.66% from the prior year.
• Accumulated Expenses eased to $88.1 million in Q1 2026 per IOVA's latest filing, from $111.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $111.2 million in Q4 2025 and bottomed at $13.5 million in Q2 2022.
• Historically, Accumulated Expenses has averaged $60.5 million across 5 years, with a median of $48.9 million in 2022.
• On a YoY basis, Accumulated Expenses climbed as much as 518.97% in 2022 and fell as far as 64.44% in 2022.
• Iovance Biotherapeutics' Accumulated Expenses stood at $20.2 million in 2022, then soared by 243.8% to $69.4 million in 2023, then increased by 18.05% to $81.9 million in 2024, then surged by 35.66% to $111.2 million in 2025, then retreated by 20.77% to $88.1 million in 2026.
• Business Quant data shows IOVA's Accumulated Expenses at $88.1 million in Q1 2026, $111.2 million in Q4 2025, and $87.3 million in Q3 2025.